Trials Presented at ESMO 2018
In patients with previously untreated advanced renal cell carcinoma (RCC) whose tumors were positive for the PD-L1 checkpoint, a combination of the checkpoint inhibitor avelumab and the tyrosine kinase inhibitor (TKI) axitinib increased the median PFS from 8.4 months to 13.8 months when compared with the TKI sunitinib (HR 0.69; P=0.0001).11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma
CIP2A is a well-known oncoprotein whose expression is elevated in multiple human solid tumor types. However, its role in renal cell carcinoma (RCC) development is poorly understood.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

The 11 most common cancers in the U.S.
Kidney cancer is one of the most common cancers in the U.S. Men are twice as likely as women to be diagnosed with kidney cancer, according to the ACS. Men's increased exposure to cancer-causing chemicals in the workplace and increased likelihood of smoking may partly explain this gap. For all people, though, the symptoms may include blood in the urine, low back pain on one side of the body that's not linked to an injury, a lump in the lower back, fatigue, appetite loss, unexplained weight loss, and more.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Clinical Trial Saves Life of Stage 4 Kidney Cancer Patient
Dallas journalist Robert Wilonsky beat the odds with help from the team at UT Southwestern.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Scientists identify potential new treatment strategy for kidney cancer
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

MDACC 2018: Debate: What is the Best Salvage Therapy After Failure of Immune Checkpoint Inhibition?
Dr. Msaouel discusses the best treatment options after failure of immune checkpoint inhibition.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

MDACC 2018: Systemic Therapy for Metastatic Non-Clear Cell Histology Patients: What Works and What Doesn ’t?
Our 2017 YIA winner Pavlos Msaouel is doing great work in kidney cancer research. In this article, he explains chemotherapy vs. targeted therapies.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

Systemic Therapy Options for Renal Cell Carcinoma
Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study
Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

Personalized Immunotherapy Combinations on Horizon
Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment, according to a presentation by Jason Luke, MD, at the 36th Annual CFS.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

Sunitinib Alone or after Nephrectomy in Renal Cancer
In the CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiog éniques) trial, Méjean et al. (Aug. 2 issue)1 determine the noninferiority of sunitinib alone, as compared with nephrectomy followed by sunitinib, on the basis of the observation that the 95% confidence interval for the hazard ratio of death did not exceed 1.20 (the noninferiority margin for t he trial).11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma
Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and more than 90% of kidney neoplasms. High rates of undiagnostic percutaneous kidney biopsies and difficulties in reliable pre-operative differentiation between malignant and benign renal tumors using contemporary imaging techniques result in large numbers of redundant surgeries.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Front-Line Combo Found Superior for Advanced RCC
Avelumab plus axitinib combination therapy is associated with better outcomes compared with sunitinib alone as first-line treatment of advanced renal cell carcinoma (RCC), according to study findings presented at the European Society for Medical Oncology 2018 Congress in Munich, Germany.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Distress Levels High Among Patients With Common Form of Kidney Cancer
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy
Despite the evolution of systemic therapy from the immunotherapy to targeted therapy eras, surgical management remains a mainstay of treatment of patients with locally advanced, lymph node-positive, and distant metastatic renal cell carcinoma.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy
Durable response, inherent or acquired resistance, and dose-limiting toxicities continue to represent major barriers in the treatment of patients with advanced clear-cell renal cell carcinoma (ccRCC).11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Comprehensive assessment gene signatures for clear cell renal cell carcinoma prognosis
There are many prognostic gene signature models in clear cell renal cell carcinoma (ccRCC). However, different results from various methods and samples are hard to contribute to clinical practice. It is necessary to develop a robust gene signature for improving clinical practice in ccRCC. A method was proposed to integrate least absolute shrinkage and selection operator and multiple Cox regression to obtain mRNA and microRNA signature from the cancer genomic atlas database for predicting prognosis of ccRCC.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Tivozanib Improves PFS in Highly Refractory RCC
The VEGF inhibitor tivozanib (Fotivda) reduced the risk of disease progression or death by 26% compared with sorafenib (Nexavar) in patients with highly refractory advanced or metastatic renal cell carcinoma (RCC), according to topline findings from the phase III TIVO-3 trial.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Limiting protein intake may enhance response to immunotherapy
Restricting protein intake may improve responses to immunotherapy, according to study results published in Clinical Cancer Research.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Tivozanib extends PFS in advanced renal cell carcinoma
Tivozanib extended PFS compared with sorafenib among patients with highly refractory advanced or metastatic renal cell carcinoma, according to randomized phase 3 study results released by the agent ’s manufacturer.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). The role of cabozantinib has not been established in non-clear cell renal cell carcinoma (nccRCC).11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan
Sunitinib has been shown to offer clinical benefits during the treatment of advanced renal cell carcinoma. However, molecular targeting drugs are expensive and can have a significant impact on medical expenses.11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

Clinical Utility of Chromosome Genomic Array Testing for Unclassified and Advanced-Stage Renal Cell Carcinomas
Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost.11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
AVEO Oncology today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company ’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC).11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

Sunitinib vs Nephrectomy Followed by Sunitinib in Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Arnaud M éjean, MD, PhD, of the Hôpital Européen Georges Pompidou, and colleagues found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.10/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2018 Category: Urology & Nephrology Source Type: news

Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
EUSA Pharma (EUSA) welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.10/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2018 Category: Urology & Nephrology Source Type: news

Combination immunotherapy with IL-2 surface-modified tumor cell vaccine and PD-1 blockade against renal cell carcinoma
Studies show that immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma.10/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news

Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news

Tall people at greater risk of cancer, study says
Colon and kidney cancer and lymphoma were among the types of cancer for which the correlation was strongest.10/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 25, 2018 Category: Urology & Nephrology Source Type: news

Eating Organic Food May Reduce Cancer Risk
A new study published in JAMA Internal Medicine suggests those who frequently eat organic foods may have a lower risk of developing cancer.10/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 25, 2018 Category: Urology & Nephrology Source Type: news

LoginSearchLATEST A look ahead to key trial readouts at ESMO
ESMO is only 7 days away. Here is an inside look at some of the trials that will be discussed.10/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 12, 2018 Category: Urology & Nephrology Source Type: news

8 Surprising Health Benefits of Wakame Seaweed
Wakame seaweed may have cancer-fighting properties. A study found that specific compounds extracted from the seaweed were effective at inhibiting the growth of colon and kidney cancer cells.10/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 12, 2018 Category: Urology & Nephrology Source Type: news

Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
Cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23, 2018 in Munich, Germany.10/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 9, 2018 Category: Urology & Nephrology Source Type: news

Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance.10/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 8, 2018 Category: Urology & Nephrology Source Type: news

No link between progression-free survival, quality of life in cancer trials
In clinical trials evaluating cancer interventions, there was no significant association between progression-free survival and health-related quality of life, according to research published in JAMA Internal Medicine.10/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 5, 2018 Category: Urology & Nephrology Source Type: news

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma
The use of robotic tumor enucleation conferred favorable long-term surgical margins and local recurrence rates in patients with sporadic renal cell carcinoma (RCC), according to the results of a single-center Italian study.10/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 4, 2018 Category: Urology & Nephrology Source Type: news

A New Front Line Is Taking Shape in Metastatic Renal Cell Carcinoma
The dismal prognosis for patients with metastatic renal cell carcinoma (mRCC) has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.10/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 4, 2018 Category: Urology & Nephrology Source Type: news

What Makes the Nobel-Winning Breakthroughs in Immunotherapy So Revolutionary Read more: https://www.smithsonianmag.com/science-nature/nobel-winning-breakthroughs-in-immunotherapy-revolutionary-1809704
This article by Smithsonian Magazine explains the importance of this approach in treating cancer.10/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 4, 2018 Category: Urology & Nephrology Source Type: news

Epidemiology of Renal Cell Carcinoma
Smoking, obesity, hypertension and chronic kidney disease are risk factors for kidney cancer.09/28/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 28, 2018 Category: Urology & Nephrology Source Type: news

Renal Cell Carcinoma Center of Excellence
We invite you to become a member of PracticeUpdate and the Renal Cell Carcinoma Center of Excellence, an expert-curated resource that ’s dedicated to practicing physicians. The Renal Cell Carcinoma Center of Excellence provides physicians with the most up to date information on patient care.09/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2018 Category: Urology & Nephrology Source Type: news

New nanotherapy offers hope in treating drug-resistant renal cell carcinoma
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.09/26/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 26, 2018 Category: Urology & Nephrology Source Type: news

Obesity could overtake smoking as biggest preventable cause of cancer in women
Being overweight or obese as an adult increases the risk of 13 different types of cancer including breast, bowel and kidney cancer, but only around one in seven people in the UK are aware of the link.09/24/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 24, 2018 Category: Urology & Nephrology Source Type: news

Susan describes her cancer diagnosis at age 25
Susan from Alberta, Canada, was diagnosed with stage 1 kidney cancer at age 25. After receiving a radical right nephrectomy, she has remained cancer-free for 12 years. Below, Susan shares her best advice for those going through a similar situation: 1.) Ask questions and record everything so you can remember what the doctor says. It will also serve as a journal for you down the road. 2.) Be kind to yourself. There will be bad days, hard days, but there will be many good days as well so enjoy those when they come. 3.) Let your close loved ones know when you are having a bad day, don ’t keep your feelings to yourself...
Source: Kidney Cancer Association - September 20, 2018 Category: Urology & Nephrology Source Type: news

NLR Predicts Survival After Cytoreductive Nephrectomy+Thrombectomy
Preoperative neutrophil-lymphocyte ratio (NLR) may predict survival following cytoreductive nephrectomy plus thrombectomy for renal cell carcinoma (RCC), a new study suggest.09/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 19, 2018 Category: Urology & Nephrology Source Type: news

Kidney Cancer: Risk Factors and Prevention
This article discusses the risk factors that can cause kidney cancer and what people can do to lower their chances of developing the condition.09/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 19, 2018 Category: Urology & Nephrology Source Type: news

Combinations Poised to Carry Clinical Benefit in RCC
In this Q&A article, Bradley McGregor, M.D., explains how combination therapy will have a global impact on patients.09/18/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 18, 2018 Category: Urology & Nephrology Source Type: news